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Abstract
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of
proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of
the c-ABL gene within hematopoietic stem cells and hemangioblasts in the bone marrow. The ability to suppress
almost completely, both in terms of phenotype and cytogenetically, the myeloid cell line expansion by imatinib
mesylate is indicative of a phenomenon that depends strictly on the transformed status of the cell of origin in the
chronic myeloid leukemia process. It is with relevance to complex participation of the dynamics of the fused BCR-
ABL protein product that contextual conditioning of the cells of origin of the gene translocation further motivates the
dimensional expansion of the transformed myeloid cell clones to increasing proliferative rates, thus leading to blast
crisis as eventual loss of differentiating potential.
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Introduction
The targeting of the hematopoietic stem cells bearing BCR-ABL
translocation fusion gene is sufficient for phenotypic control of the
proliferating myeloid cells in patients suffering from the chronic phase
of chronic myeloid leukemia. Noncoding RNAs are involved in CML
in particular, by regulating gene expression through binding to target
mRNAs [1]. The dimensions of such suppression, however, allow for
persistence of non-replicating hematopoietic stem cells in patients
treated with imatinib mesylate. Imatinib has potent anti-cancer effect
against leukemia associated with BCR-ABL and with solid tumors
over-expressing c-kit and Platelet Derived Growth Factor Receptor [2].
Within such scenario, the question arises whether hemangioblasts are a
real primary target for BCR-ABL fusion translocation; such possibility
is significant in the possible realization of involvement of both
hematopoietic stem cells and endothelial cells in malignant
transformation, as has also been suggested in breast carcinoma and
glioblastoma lesions.
Primitive Cell of Origin
Such considerations indicate the directive involvement of a
primitive cell line that is primarily non-differentiated but capable of
significant divergent potential for differentiation as multi-potent cells
of involvement in the transformation process. S-phase progression of
the cell-cycle may be inhibited against lymphoid crisis in CML and
Philadelphia chromosome-positive acute lymphoblastic leukemia [3].
The inclusive phenomenon of malignant transformation in the
initial stages of chronic myeloid leukemia is derived from
considerations also of the quiescent nature of such cells that, to a
significant degree, prove to be elements of diversity in the dual process
of transformation and of mitogenesis of the targeted cells.
Chronic Phase
In line with the development of the chronic phase of chronic
myeloid leukemia, there arises a complex derivation of the BCR-ABL
fusion gene that is cytogenetically recognizable as the Philadelphia
chromosome [Ph]. In 98% of CML patients with the Ph chromosome,
there develops cleavage of the BCR gene within its major breakpoint
region and breakage of the ABL within a 100-kbp region of exon 2a [4].
The intricate definition of the nature of the constitutive activation
status of the tyrosine kinase domain of the ABL gene is linked to an
overlapping break point of the BCR gene in the process of reciprocal
translocation. Region choice for canonical siRNA design algorithms is
restricted in a fusion junction site as BCR-ABL but potency may be
enhanced by optimization outside of target sequence [5]. The
mechanics of the translocation process itself between ABL and BCR
appear obscure but might be implicated within the general presence of
BCR-ABL fusion gene even in healthy individuals, albeit at low levels.
The discovery of oncogenic drives and development of targeted
therapies such as imatinib has markedly improved outcome in CML
patients [6]. Cancer cells efficiently utilize limited energy sources, and
drugs that target cellular metabolism further improve the efficacy of
imatinib therapy [7].
Such presence in patients, who do not in fact constitute early stages
of chronic myeloid leukemia indicates a possible emergence of normal
physiologic roles of ABL, within normal contextual conditioning of
hematopoietic cells. In such manner, c-ABL is abundant especially
within the cytosol and is present also combined with nuclear
chromatin.
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The BCR-ABL fusion protein product appears therefore to actively
constitute an essentially over-amplified consequential process that is
beyond simple considerations of parametric homeostatic control.
Metastasis suppressor 1 is downregulated in hematopoietic stem and
progenitor cells in patients with CML [8]. It is such quantitative over-
expression of the tyrosine kinase activity that would promote a
constitutive potentiality for expression of such tyrosine kinase. Also,
variant complex translocations involving a third chromosome may be
present in 5-8% of CML patients [9].
Significant is the emergence of the p120 BCR-ABL fusion protein as
the common isoform in the development of growth-factor
independence of the malignant myeloid cell proliferation in CML
patients. By contrasting the conformational free energy landscape of
mutants resistant to imatinib action with those of the wild-type
tyrosine kinases it is possible to better understand the emergence of
drug resistance [10].
Phenotype
Consideration of the chronicity of the transformed myeloid cells is
relative to advanced stages of the disease where blast crisis emerges in
terms that phenotypically are expressed by both high proliferative rates
and also as essential non-differentiation status; such blast cells are
reflected in the generation of a large range of additional genetic lesions
and also in the insensitivity of the tyrosine kinase activity to
suppression by imatinib mesylate. Proteolysis Targeting Chimera
technology utilizes small molecules that recruit target proteins such as
BCR-ABL and c-ABL for the ubiquitination-proteosome for
degradation [11].
It would appear that translocation in the generation of the BCR-
ABL fusion gene occurs essentially within non-proliferative stem cells
in a manner that is strictly cell-context dependent.
The realization of further expansion of the clonal proliferation of
multi-potent cells is further indicative of possible primary targeting of
the hemangioblast in a manner that bridges hemopoiesis and
endothelial vascular genesis within the bone marrow, in early stages of
transformation in CML patients. Mutations in chromatin regulators
often result in more stem-like cells that seed a bulk leukemic
population and therapeutic agents targeting these regulators are being
developed [12].
BCR-ABL Transformation
The derivative dimensions included within the establishment status
of the BCR-ABL translocation allow for a permissive production of the
corresponding fusion protein that may exceed the controllable limit of
action of the highest tolerable levels achieved by imatinib mesylate
therapy. Hyaluronan oligomers sensitize CML cells to the anti-
proliferative effect of imatinib by increasing apoptosis and senescence
[13].
The mechanism and natural history of CML is still unclear [14].
Hence, it is significant to view the c-ABL as potential overlap
phenomenon with the BCR-ABL fusion gene in determining the
nature of the malignant transformation process within hematopoietic
stem cell and hemangioblast as a combined integral phenomenon of
synergistic enhancement.
The further compounding effects of such synergism are reflected in
a dual population of cell types that ensure the promoted
transformation event as essential establishment and maintenance of
the tyrosine kinase over-activity in terms especially of constitutive
activation. There is a significant association of defective apoptosis
arising from promoter polymorphisms of Fas-FasL genes with the
development of CML [15].
Experimental Transfer
Biologic ineffectiveness in transfer of malignant transformation to
many cell lines and to murine models indicates the failed susceptibility
of a number of cell types to the establishment of early stages of
oncogenesis in CML, in vitro and in vivo. The lack of a faithful model
of the chronic phase of CML in the laboratory testifies to poorly
understood dynamics of the translocation/fusion phenomenon in
genesis of the BCR-ABL gene complex, and especially to the
breakpoint dynamics of both BCR and ABL, but particularly within the
breakage cluster regions of the BCR gene. In particular, the therapeutic
resistance by the gatekeeper mutation T315I in BCR-ABL to imitinib is
a significant problem clinically [16], but pyrazolopyrimides may serve
as lead compounds for development. MicroRNA employing non-viral
vectors have been utilized to inhibit various cancer cells, and may
prove useful in CML hematopoietic stem cells [17].
Hemangioblast/Hematopoietic Stem Cell
ABL has been recognized as essential for the transformation process
whereas the BCR appears to contribute to the maintenance of
establishment and proliferation of the proliferating clone expansion in
CML. Such considerations indicate the emergence of individual gene
effects within complex realization of effects in oncogenesis.
Modulation of aging-related inflammation within the bone marrow
micro-environment may enhance the emergence of oncogenic events
in stem cells [18]. Isohiocyanate treatment may correct inflammatory
and defective DNA repair mechanisms in hematopoietic tissues [19].
The development of effective contextual requirement for the specific
cellular micro-environment is dependent on the active genesis of the
translocation event itself, but this also promotes the participation of
the possible dual relevance of the hemangioblast and hematopoietic
stem cell in malignant transformation.
Dysregulated cholesterol metabolism and/or accumulation occur in
leukemia, and 2-hydroxypropyl-beta-cyclodextrin shows anti-CML
effects by modifying cholesterol [20].
The pool of quiescent hematopoietic stem cells and the further
possible forms of co-operability of hemangioblasts in malignant
transformation indicate a basic dualism that is further defining
dimension for contextual cellular requirements in the oncogenesis of
CML. Dasatinib is a novel, multi-targeting kinase inhibitor of
breakpoint cluster region Abelson [BCR-ABL] and Src family kinases,
with a time-dependent anti-leukemic effect [21].
Parameters of multi-potentiality of these cells allow for a
permissiveness of excessive proliferative cells that progress in terms of
added realized constitutive activation of the tyrosine kinase of the
fused ABL. The development of selective kinase inhibitors is
challenging due to the large size of the kinome and the structural
similarity between kinase active sites [22]. Multi-targeting of both
BCR-ABL kinase and microtubules may be achieved with 2-
acylaminothiophene-3-carboxamides [23].
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Genetic Instability
Dimensional correlation allows for the recognition of malignant
permissiveness that correlates with possible generation of genetic
instability, and thus to the generation of accumulated genetic defects
within the neoplastic cells. Under-expression of miR-130a functions as
tumor suppressor by inhibiting multiple anti-apoptosis proteins
including BCL-2 [24]. Added to such phenomenon, however, is the
significant phenotypic suppression of the malignant myeloid cells by
primarily targeting the cells of origin of the chronic phase of CML.
More inhibitors of the mutated ABL tyrosine kinase are absolutely
required [25]. Inhibitors of BCR-ABL tyrosine kinase kill CML cells by
stimulating pro-apoptotic BIM and inhibiting anti-apoptotic BCL2,
BCLxL and MCL1 [26].
Diversity in Transformation
Diversity of potential transformation is hence linked to the multi-
potentiality of the cancer stem cell concept for oncogenesis but this is
itself conditioned by dimensions found within the microenvironment
of the bone marrow.
Such conditioning appears linked to the homeostatic functions of
the c-ABL gene in enhancing intercellular adhesion and
communication, on the one hand, and also of the determined cellular
morphology of the targeted cells. Indicative parameters include
integrin signaling and also a binding of the ABL to the actin within the
cytosol of the cells concerned. A cytosol-nuclear transport also is
relevant in that the BCR-ABL fusion protein loses nuclear target
potential. Hence the relevance of strict dynamics of the BCR-ABL
fusion protein is critical in the ongoing process in CML oncogenesis
that is accompanied by a wide variety of down-stream signaling
pathways such as Jun, STAT5, Ras pathway. Included also is the
implied dysfunction of the 20S proteasome-ubiquitin mechanisms.
Better understanding of CML hematopoietic stem cell biology is
required to eradicate these cells responsible for disease recurrence and
of residual disease [27].
Alternative Pathways and Blast Crisis
CML therefore emerges as a series of alternative pathways of
proliferation, on the one hand, and of differentiation pathways that are
operative within the pool of differentiated malignant myeloid cells in
patients who enter the chronic phase of the CML. Highly significant is
the further advanced disease-state where differentiating potential is
lost within contextual conditioning in establishment of higher
proliferative rates of the malignant cells.
The BCR-ABL fusion gene doubles the expression level of genes
involved in the regulation of the cell cycle, proliferation and apoptosis
of CD34+ cells, with implications also of modified genes in PI3K/AKT
and MAPK signaling in CML patients [28].
The blast crisis in CML patients indicates a dynamic process of
evolving oncogenesis that is inclusive phenomenon for participation of
the accumulating genetic lesions within the transformed myeloid cells.
Linked to such phenomenon is the emergence in some patients of the
p190 isoform of the BCR-ABL translocation fusion gene in patients
with the acute ALL phenotype lacking an initial chronic phase.
Overall, there develops a progression of the disease state that closely
correlates with dynamics of establishment of the malignant process
that is maintained by a BCR-ABL fusion gene. The significant
suppression possible by specific imatinib-targeting of the cell of origin
of the malignant transformation of CML indicates the highly
constitutive nature of a malignant change that is ABL-tyrosine-kinase
mediated.
Concluding Remarks
Permutation of dynamics of the BCR-ABL fusion protein lies at the
center of operative transfer of the constitutive activation of the tyrosine
kinase domain of the ABL protein. Added formulation of breakage
point involvement of the BCR and of significant participation in
establishment of the malignant phenotype within the contextual
cellular series of dual hematopoietic stem cell and of hemangioblast
would lead to the recognition of a micro-environmental series of
transforming changes inducing proliferation and anti-apoptosis
leading to the eventual creation of blast cells that do not differentiate.
Further to the systematic parameters of proliferation is added an
overall projected loss of potential differentiation that is maintained at
the expense progressively increasing proliferative activity.
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